Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
Currently, one of the leading treatments for non-small-cell lung cancer is immunotherapy involving immune checkpoint inhibitors. These monoclonal antibodies restore the anti-tumour immune response altered by negative immune checkpoint interactions. The most commonly used immunotherapeutics in monoth...
Main Authors: | Natalia Krzyżanowska, Kamila Wojas-Krawczyk, Janusz Milanowski, Paweł Krawczyk |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/6/3087 |
Similar Items
-
Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy
by: Kamila Wojas-Krawczyk, et al.
Published: (2021-08-01) -
Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
by: Natalia Krzyżanowska, et al.
Published: (2022-10-01) -
Double Guard Efficiency and Safety—Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune Checkpoints in Non-Small Cell Lung Cancer Patients
by: Ewa Kalinka, et al.
Published: (2023-07-01) -
Failure of Immunotherapy—The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer
by: Justyna Błach, et al.
Published: (2021-08-01) -
Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes
by: Jia-Tong Ding, et al.
Published: (2023-01-01)